ORIC Pharmaceuticals (ORIC) is a pre-revenue clinical-stage oncology company. Under a liquidation lens as of March 31, 2026, the recovery posture is modestly positive at the gross asset level but the useful liquidation value narrows considerably once practical haircuts are applied. Total assets of $436.8M are dominated by financial instruments: cash and equivalents of $56.4M (100% recovery), current marketable securities of $225.5M, and noncurrent marketable securities of $137.8M. Applying 95-100% recovery to the investment securities portfolio (high-quality, liquid fixed income typical of clinical-stage biotechs) yields approximately $417M in recoverable financial assets. Against total liabilities of only $21.2M—virtually all current, comprising $14.9M accrued liabilities, $3.3M current operating lease liability, $2.9M accounts payable, and $3.4M noncurrent liabilities—the net liquidation surplus is roughly $395-$415M, or approximately $3.80-$4.00 per share on 103.5M shares outstanding. MFFAIS reports a CLV/LLV/OLV of $38.6M, which appears to reflect a materially different assumption set; the XBRL-reported balance sheet suggests substantially higher recoverable value driven by the large marketable securities book. PP&E gross of $10.1M with $7.9M accumulated depreciation yields $2.1M net book; at a 50-60% liquidation haircut this contributes less than $1.5M. Intangibles and goodwill are not separately tagged. Prepaid and other current assets of $8.3M recover at 50-70% in liquidation. The liability stack is lean: no long-term debt, no pension, no production commitments disclosed in XBRL. A post-period-end event is material to the burn trajectory: on August 12, 2025, ORIC announced a ~20% workforce reduction and elimination of its discovery research group, focusing solely on rinzimetostat and enozertinib. This will reduce forward cash consumption but generates near-term severance charges not yet fully reflected in Q1 2026 financials. Q1 2026 operating cash outflow was $32.4M against a prior financing inflow of $61.1M from a May 2025 private placement. Accumulated deficit stands at $728.0M. Federal NOL carryforwards of $424.3M (per 10-Q narrative, as of December 31, 2025) have zero liquidation value given full valuation allowance. The filing discusses the August 2025 workforce reduction and associated restructuring charges in MD&A but does not separately tag restructuring accruals or severance liabilities in XBRL for this quarter, which limits precise quantification of that liability increment.
▼ Community Notes